Binding characteristics of [3H]quinupramine to rat brain membrane fractions. 1987

H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
Department of Pharmacology, Kyoto Pharmaceutical University, Japan.

The binding characteristics of [3H]quinupramine to rat brain membrane fractions were studied. The specific binding of [3H]quinupramine to rat brain membrane fractions was stable, reversible and saturable. Scatchard analysis of the data from saturation experiments indicated that the specific binding was a single population with an affinity (KD) of 3.04 nM, a maximal binding site number (Bmax) of 714 fmol/mg protein, and a Hill coefficient (nH) of 1.08. Compounds known to inhibit muscarinic cholinergic receptors such as atropine and quinuclidinyl benzilate were the most potent competitors of [3H]quinupramine binding. When the drug potencies in inhibiting [3H]quinupramine binding were tested in the presence of 10 nM atropine, mianserin was the most potent competitor. Studies of the subcellular fractions showed that there was an enrichment of [3H]quinupramine binding sites in the synaptosome fraction. The regional distribution study revealed the highest densities of binding sites in the cerebral cortex and the lowest in the cerebellum. Thus, the specific binding of [3H]quinupramine observed here can be accounted for by both muscarinic cholinergic and serotonin S2 receptors.

UI MeSH Term Description Entries
D008297 Male Males
D011812 Quinuclidines A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group. Quinuclidine
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003984 Dibenzazepines Compounds with two BENZENE rings fused to AZEPINES.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000929 Antidepressive Agents, Tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. Antidepressants, Tricyclic,Tricyclic Antidepressant,Tricyclic Antidepressant Drug,Tricyclic Antidepressive Agent,Tricyclic Antidepressive Agents,Antidepressant Drugs, Tricyclic,Agent, Tricyclic Antidepressive,Agents, Tricyclic Antidepressive,Antidepressant Drug, Tricyclic,Antidepressant, Tricyclic,Antidepressive Agent, Tricyclic,Drug, Tricyclic Antidepressant,Drugs, Tricyclic Antidepressant,Tricyclic Antidepressant Drugs,Tricyclic Antidepressants
D001285 Atropine An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine. AtroPen,Atropin Augenöl,Atropine Sulfate,Atropine Sulfate Anhydrous,Atropinol,Anhydrous, Atropine Sulfate,Augenöl, Atropin,Sulfate Anhydrous, Atropine,Sulfate, Atropine
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
April 1980, Life sciences,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
September 1980, Brain research,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
October 1982, European journal of pharmacology,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
April 1983, Life sciences,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
January 1987, Journal of pineal research,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
April 1981, Canadian journal of physiology and pharmacology,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
May 1996, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
March 1982, Biochemical pharmacology,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
May 1979, European journal of pharmacology,
H Sakamoto, and N Yokoyama, and T Nishimoto, and K Murai, and H Tatsumi, and S Kohno, and K Ohata
September 2003, European journal of pharmacology,
Copied contents to your clipboard!